Author

K. Millard

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Immunology· 2 Microbiology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 3 Research Focus:host-pathogen & immune response· 3 Assay:proteomics· 3 Research Focus:cell type annotation· 2 Organism:human· 2 Research Focus:clustering· 1 Research Focus:differential expression· 1 Approach:statistical model· 1

Frequent Co-Authors

A. Cho· 3 shared A. Gazumyan· 3 shared C. Gaebler· 3 shared F. Muecksch· 3 shared F. Schmidt· 3 shared M. Caskey· 3 shared M. Cipolla· 3 shared S. Finkin· 3 shared

Activity by Year

2020-2021 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersImmunology

A. Cho

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Anti- SARS-CoV-2 Receptor Binding Domain Antibody Evolution after mRNA Vaccination

A. Cho, F. Muecksch, D. Schaefer-Babajew, Z. Wang, S. Finkin, C. Gaebler, V. Ramos, M. Cipolla, P. Mendoza, M. Agudelo, E. Bednarski, J. DaSilva, I. Shimeliovich, J. Dizon, M. Daga, , M. C. Nussenzweig

This study examines memory B cell evolution 5 months after mRNA vaccination in naive individuals, finding increased neutralizing activity but no further breadth or potency, and higher overall plasma neutralizing potency compared to natural infection.

bioRxiv · Jul 29, 2021Immunology

Development of potency, breadth and resilience to viral escape mutations in SARS-CoV-2 neutralizing antibodies

F. Muecksch, Y. Weisblum, C. Barnes, F. Schmidt, D. Schaefer-Babajew, J. Lorenzi, A. Flyak, A. DeLaitsch, K. Huey-Tubman, S. Hou, C. Schiffer, C. Gaebler, Z. Wang, J. Da Silva, D. Poston, , P. Bieniasz

This study examines how somatic mutations in SARS-CoV-2 antibodies affect their neutralization potency, breadth, and resistance to escape mutations across six antibody lineages.

bioRxiv · Mar 7, 2021 · PreprintMicrobiology

Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals

D. F. Robbiani, C. Gaebler, F. Muecksch, J. Cetrulo Lorenzi, Z. Wang, A. Cho, M. Agudelo, C. Barnes, S. Finkin, T. Hagglof, T. Oliveira, C. Viant, A. Hurley, K. Millard, R. Kost, , Nuss

The paper analyzes antibody responses in convalescent individuals, finding low neutralizing titers but rare potent RBD-specific antibodies with broad antiviral potential.

bioRxiv · May 13, 2020Immunology